Caseware UK (AP4) 2025.0.111 2025.0.111 2025-02-28 2025-02-28 14 2024-03-01 false Pharmacy 15 true true The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 07353189 2024-03-01 2025-02-28 07353189 2023-03-01 2024-02-29 07353189 2025-02-28 07353189 2024-02-29 07353189 c:Director1 2024-03-01 2025-02-28 07353189 d:Buildings d:ShortLeaseholdAssets 2024-03-01 2025-02-28 07353189 d:Buildings d:ShortLeaseholdAssets 2025-02-28 07353189 d:Buildings d:ShortLeaseholdAssets 2024-02-29 07353189 d:PlantMachinery 2024-03-01 2025-02-28 07353189 d:PlantMachinery 2025-02-28 07353189 d:PlantMachinery 2024-02-29 07353189 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 07353189 d:MotorVehicles 2024-03-01 2025-02-28 07353189 d:MotorVehicles 2025-02-28 07353189 d:MotorVehicles 2024-02-29 07353189 d:MotorVehicles d:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 07353189 d:FurnitureFittings 2024-03-01 2025-02-28 07353189 d:FurnitureFittings 2025-02-28 07353189 d:FurnitureFittings 2024-02-29 07353189 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 07353189 d:OfficeEquipment 2024-03-01 2025-02-28 07353189 d:OfficeEquipment 2025-02-28 07353189 d:OfficeEquipment 2024-02-29 07353189 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 07353189 d:ComputerEquipment 2024-03-01 2025-02-28 07353189 d:ComputerEquipment 2025-02-28 07353189 d:ComputerEquipment 2024-02-29 07353189 d:ComputerEquipment d:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 07353189 d:OwnedOrFreeholdAssets 2024-03-01 2025-02-28 07353189 d:CurrentFinancialInstruments 2025-02-28 07353189 d:CurrentFinancialInstruments 2024-02-29 07353189 d:Non-currentFinancialInstruments 2025-02-28 07353189 d:Non-currentFinancialInstruments 2024-02-29 07353189 d:CurrentFinancialInstruments d:WithinOneYear 2025-02-28 07353189 d:CurrentFinancialInstruments d:WithinOneYear 2024-02-29 07353189 d:ShareCapital 2025-02-28 07353189 d:ShareCapital 2024-02-29 07353189 d:RetainedEarningsAccumulatedLosses 2025-02-28 07353189 d:RetainedEarningsAccumulatedLosses 2024-02-29 07353189 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2025-02-28 07353189 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2024-02-29 07353189 c:FRS102 2024-03-01 2025-02-28 07353189 c:AuditExemptWithAccountantsReport 2024-03-01 2025-02-28 07353189 c:FullAccounts 2024-03-01 2025-02-28 07353189 c:PrivateLimitedCompanyLtd 2024-03-01 2025-02-28 07353189 2 2024-03-01 2025-02-28 07353189 e:PoundSterling 2024-03-01 2025-02-28 iso4217:GBP xbrli:pure

Registered number: 07353189 HEALTHY CHOICE PHARMA LTD UNAUDITED FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 28 FEBRUARY 2025
HEALTHY CHOICE PHARMA LTD CHARTERED ACCOUNTANTS' REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OFHEALTHY CHOICE PHARMA LTD FOR THE YEAR ENDED 28 FEBRUARY 2025 In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Healthy Choice Pharma Ltd for the year ended 28 February 2025 which comprise the Balance sheet and the related notes from the Company's accounting records and from information and explanations you have given to us. This report is made solely to the director of Healthy Choice Pharma Ltd in accordance with the terms of our agreement. Our work has been undertaken solely to prepare for your approval the financial statements of Healthy Choice Pharma Ltd and state those matters that we have agreed to state to him in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Healthy Choice Pharma Ltd and its director for our work or for this report. It is your duty to ensure that Healthy Choice Pharma Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the Company's assets, liabilities, financial position and profit. You consider that Healthy Choice Pharma Ltd is exempt from the statutory audit requirement for the . We have not been instructed to carry out an audit or review of the financial statements of Healthy Choice Pharma Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements. Shipleys Tax Planning 2 March 2026 Page 1
HEALTHY CHOICE PHARMA LTD REGISTERED NUMBER: 07353189 BALANCE SHEET AS AT 28 FEBRUARY 2025
|  | 28 February |  | 29 February
|  | 2025 |  | 2024
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Tangible assets | 4 |  | 59,756 |  | 12,600
|  |  | 59,756 |  | 12,600
Current assets |  |  |  |  |
Stocks |  | 92,500 |  | 92,050 |
Debtors: amounts falling due after more than one year | 5 | 1,310,000 |  | 1,310,000 |
Debtors: amounts falling due within one year | 5 | 569,673 |  | 505,153 |
Cash at bank and in hand | 6 | 501,827 |  | 576,500 |
|  | 2,474,000 |  | 2,483,703 |
Creditors: amounts falling due within one year | 7 | (601,108) |  | (676,050) |
Net current assets |  |  | 1,872,892 |  | 1,807,653
Total assets less current liabilities |  |  | 1,932,648 |  | 1,820,253
Net assets |  |  | 1,932,648 |  | 1,820,253
Capital and reserves |  |  |  |  |
Called up share capital |  |  | 100 |  | 100
Profit and loss account |  |  | 1,932,548 |  | 1,820,153
|  |  | 1,932,648 |  | 1,820,253
The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 2 March 2026. Page 2
HEALTHY CHOICE PHARMA LTD REGISTERED NUMBER: 07353189 BALANCE SHEET (CONTINUED) AS AT 28 FEBRUARY 2025
Mohammad Hassan
Director
The notes on pages 4 to 10 form part of these financial statements. Page 3
HEALTHY CHOICE PHARMA LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2025
1. | General information
Healthy Choice Pharma Ltd is a company domiciled in England & Wales, registration number 07353189. The registered office is Dewsbury Pharmacy, Healds Road Medical Centre, Healds Road, Dewsbury, WF13 4HT. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the requirements and the Companies Act 2006 and the requirements of the Statement of Recommended Practice 'Accounting by Limited Liabilities Partnerships'. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. The following principal accounting policies have been applied:
| 2.2 | Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Sale of goods Revenue from the sale of goods is recognised when all of the following conditions are satisfied: ∙the Company has transferred the significant risks and rewards of ownership to the buyer; ∙the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the transaction; and ∙the costs incurred or to be incurred in respect of the transaction can be measured reliably. Rendering of services Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the contract; ∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and ∙the costs incurred and the costs to complete the contract can be measured reliably. Page 4
HEALTHY CHOICE PHARMA LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2025 2.Accounting policies (continued)
| 2.3 | Operating leases: the Company as lessee
Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term. Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.
| 2.4 | Interest income
Interest income is recognised in profit or loss using the effective interest method.
| 2.5 | Taxation
Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.
| 2.6 | Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method. Depreciation is provided on the following basis:
|  |  |  | Short-term leasehold property | - |  | 15 years
|  |  |  | Plant and machinery | - | 25% |
|  |  |  | Motor vehicles | - | 33% |
|  |  |  | Fixtures and fittings | - | 25% |
|  |  |  | Office equipment | - |  |
|  |  |  | Computer equipment | - | 33% |
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss. Page 5
HEALTHY CHOICE PHARMA LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2025 2.Accounting policies (continued)
| 2.7 | Stocks
Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a weighted average basis. Work in progress and finished goods include labour and attributable overheads. At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.
| 2.8 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.9 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.10 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
3. | Employees
| The average monthly number of employees, including directors, during the year was 14 (2024 - 15).
Page 6
HEALTHY CHOICE PHARMA LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2025
4. | Tangible fixed assets
|  | Short-term leasehold property | Plant and machinery | Motor vehicles | Fixtures and fittings | Office equipment
|  | £ | £ | £ | £ | £
| Cost or valuation |  |  |  |  |
| At 1 March 2024 | - | 4,606 | 13,200 | 72,305 | -
| Additions | 55,174 | - | - | - | 825
| At 28 February 2025 | 55,174 | 4,606 | 13,200 | 72,305 | 825
| Depreciation |  |  |  |  |
| At 1 March 2024 | - | 3,543 | 13,200 | 60,901 | -
| Charge for the year on owned assets | 3,678 | 1,063 | - | 3,763 | 206
| At 28 February 2025 | 3,678 | 4,606 | 13,200 | 64,664 | 206
| Net book value |  |  |  |  |
| At 28 February 2025 | 51,496 | - | - | 7,641 | 619
| At 29 February 2024 | - | 1,063 | - | 11,404 | -
Page 7
HEALTHY CHOICE PHARMA LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2025 4.Tangible fixed assets (continued)
|  | Computer equipment | Total
|  | £ | £
| Cost or valuation |  |
| At 1 March 2024 | 2,839 | 92,950
| Additions | - | 55,999
| At 28 February 2025 | 2,839 | 148,949
| Depreciation |  |
| At 1 March 2024 | 2,706 | 80,350
| Charge for the year on owned assets | 133 | 8,843
| At 28 February 2025 | 2,839 | 89,193
| Net book value |  |
| At 28 February 2025 | - | 59,756
| At 29 February 2024 | 133 | 12,600
Page 8
HEALTHY CHOICE PHARMA LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2025
5. | Debtors
|  |  |  |  | 28 February | 29 February
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Due after more than one year |  |
| Other debtors | 1,310,000 | 1,310,000
|  | 1,310,000 | 1,310,000
|  |  |  |  | 28 February | 29 February
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Due within one year |  |
| Trade debtors | 384,341 | 422,337
| Other debtors | 185,332 | 82,816
|  | 569,673 | 505,153
6. | Cash and cash equivalents
|  |  |  |  | 28 February | 29 February
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Cash at bank and in hand | 501,827 | 576,500
|  | 501,827 | 576,500
7. | Creditors: Amounts falling due within one year
|  |  |  |  | 28 February | 29 February
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Trade creditors | 249,356 | 233,738
| Corporation tax | 28,151 | 105,139
| Other taxation and social security | 1,599 | 2,881
| Other creditors | 140,500 | 154,500
| Accruals and deferred income | 181,502 | 179,792
|  | 601,108 | 676,050
Page 9
HEALTHY CHOICE PHARMA LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2025
8. | Financial instruments
|  |  |  |  | 28 February | 29 February
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Financial assets |  |
| Financial assets measured at fair value through profit or loss | 501,827 | 576,500
| Financial assets measured at fair value through profit or loss comprise of cash at bank and in hand.
9. | Related party transactions
| During the year there was no movement in the loan owed by Avicenna Investments Ltd (a related party by way of connection to the shareholder JK Medical Services Ltd). At the balance sheet date other debtors due after more than one year included £380,000 (2024: £380,000) as amounts owed by Avicenna Investments Ltd. During the year there was no movement in the loan owed by Overdrive Motor Repairs Ltd (a related party by way of connection to the shareholder JK Medical Services Ltd). At the balance sheet date other debtors due after more than one year included £380,000 (2024: £380,000) as amounts owed by Overdrive Motor Repairs Ltd. During the year there was no movement in the loan owed by Hassan Pharmacare Ltd (a company owned by the director Mohammed Hassan). At the balance sheet date other debtors due after more than one year included £150,000 (2024: £150,000) as amounts owed by Hassan Pharmacare Ltd. During the year there was no movement in the loan owed by JK Medical Services Ltd (a shareholder of the company). At the balance sheet date other debtors due after more than one year included £400,000 (2024: £400,000) as amounts owed by JK Medical Services Ltd. During the year the company paid £77,000 (2024: £NIL) to Avicenna Investments Ltd for consultation services. They company is connected to Dr Khan, whose spouse is a shareholder of JK Medical Services Ltd; a shareholder owning 80% of Healthy Choice Pharma Ltd.
Page 10